Nov
20
Part 2: Why FeNO first? Spotlight on testing & special cases In Part 1, we explored the redefined approach to asthma diagnosis under the new NICE/BTS/SIGN guidelines. In Part 2, we dive deeper into the role of Fractional exhaled Nitric Oxide (FeNO) testing, looking at why it is now a...
read more →
Nov
13
Part 1: Understanding the changes – Asthma diagnosis & first steps in the new guidelines In light of the recent update to the National Institute of Care Excellence (NICE) guidelines for asthma care and management, Bedfont® Scientific Limited sponsored an informative webinar by Intermedical (UK) Limited. Seasoned respiratory nurse Carol...
read more →
Nov
06
The NObreath® device enhances access to FeNO diagnostics in Mexico. Bedfont® Scientific Limited, a world leader in breath analysis with nearly 50 years of expertise in the medical breath analysis industry, has formed a strategic partnership with Aerosol Medical Systems to improve Fractional exhaled Nitric Oxide (FeNO) testing accessibility in Latin...
read more →
Oct
31
Research has shown that seven out of ten people with asthma report that cold air exacerbates their asthma symptoms1. As winter approaches quickly, it is essential to prepare for asthma management in advance. A vital tool in asthma management, as recommended by the National Institute for Health and Care Excellence...
read more →
Aug
18
September sees the return to school for children after the summer holidays. While the return to routine is welcomed, it can be challenging for children with asthma. Research by Asthma + Lung UK found that in 2022/2023, there was a 348% rise in hospital admissions in 5-14-year-olds with an asthma...
read more →
May
28
Fractional exhaled Nitric Oxide (FeNO) is extensively utilised in both primary and secondary care settings worldwide. Many regions recommend FeNO-guided management as part of their clinical protocols. This article reviews FeNO-related guidelines in the UK and internationally, with a focus on comparing approaches across different regions. Guidelines NICE, BTS, and...
read more →
May
12
The latest UK asthma guidelines1 have identified how Fractional exhaled Nitric Oxide (FeNO) testing fits into the diagnosis and ongoing management of asthma. The guidelines are based on the latest clinical evidence, cost-effectiveness, and cost-effective modelling, so they are strongly recommended for use. But what does that mean for the individual...
read more →
Apr
25
Asthma is one of the most common long-term health conditions, so why does access to diagnosis and treatment still depend on where you live, who you see, or even your ethnicity? To mark World Asthma Day, we spoke with Carol Stonham MBE, a leading respiratory nurse, about what true accessibility...
read more →
Apr
09
Bedfont® Scientific Limited promotes FeNO testing for asthma management. Research from Asthma + Lung UK has found a significant rise in Accident and Emergency (A&E) visits from people experiencing breathing issues such as asthma. Asthma + Lung UK is a British charity formed in January 2020, with a dedication to...
read more →
Apr
03
How FeNO testing with the NObreath® can aid an early asthma diagnosis in children. As the world prepares to observe World Health Day on April 7th, 2025, Bedfont® Scientific Limited highlights the importance of early and accurate asthma diagnosis with its innovative NObreath® Fractional exhaled Nitric Oxide (FeNO) device. Whilst...
read more →
« Previous Page — Next Page »
